esophageal carcinoma
Conditions
Interventions
Case series:A clinical study on the feasibility and safety of minimally invasive everted esophagectomy through neck and abdomen incision
Sponsors
Department of Thoracic Surgery, First Affiliated Hospital of Xi’an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. aged>18 years male and female; 2. Solid tumors of the esophageal squamous cell carcinoma confirmed by cytology or histology and requiring surgical treatment; 3. Tumor stage was confirmed as T1-2N0-1M0 stage by ultrasonic gastroscopy /CT before surgery.Or T3N1M0(IIIa) stage patients were evaluated to reach PR (partial remission) after neoadjuvant radiation/chemotherapy,and surgical resection was feasible; 4. The tumor is located in the thoracic or abdominal esophagus; 5. The tumor did not invade important peripheral organs and distant metastases; 6. No evidence of significant swelling or distant metastasis in supraclavicular and retroperitoneal lymph nodes (M0); 7. The function of main organs is basically normal:lung function is basically normal and general anesthesia is acceptable.The NYHA level of cardiac function is 0-1; 8. Voluntarily signed informed consent before study, patients and/or its legal representatives have the ability to test content, process and possible adverse reactions to fully understand, and to comply with the requirements of the scheme can make the patient visits; 9. Negative and lactating women of childbearing age must be a pregnancy test, and confirm that both men and women patients are receiving recognition method of contraception by researchers, agreed to since signed informed consent to research keep within 3 months after the birth control.
Exclusion criteria
Exclusion criteria: 1. Patient with other malignant tumors at the same time; 2. Patient with previous history of esophageal or gastric resection; 3. Patient with previous history of mediastinal surgery or the abdominal cavity is widely adherent; 4. Patient with cardiac thrombosis; 5. Patient with mental, mental or neurological disorders; 6. Patient with cachexia and severe malnutrition; 7. Recent history of recurrent gastric ulcers,bleeding from the stomach and other serious underlying diseases; 8. Patient with surgical contraindications such as coagulation dysfunction, HIV antibody positive, severe infection with poor clinical control, etc; 9. Patient with other concomitant diseases (such as liver and kidney dysfunction, etc.) or combined drugs were judged by the researchers to have an impact on the results of this study; 10. Patients who were also involved in another clinical study at the same time; 11. Patients who are known to be allergic or allergic to the material of the surgical instrument; 12. Not suitable for this clinical trial by other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Perioperative complication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| survival follow-up; | — |
Countries
China
Contacts
Public ContactYong Zhang
Department of Thoracic Surgery, First Affiliated Hospital of Xi’an Jiaotong University
Outcome results
None listed